Opening book details…
About this Medicine article
RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results by Petrylak, D P; Sternberg, C N; Drakaki, A; de Wit, R; Nishiyama, H; Necchi, A; Castellano, D; Bamias, A; Chi, K N; van der Heijden, M S; Matsubara, N; Hussain, S; Flechon, A; Alekseev, B Y; Yu, E Y; Walgren, R A; Russo, F; Zimmermann, A H; Bell-Mcguinn, K M; Powles, T B is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Petrylak, D P; Sternberg, C N; Drakaki, A; de Wit, R; Nishiyama, H; Necchi, A; Castellano, D; Bamias, A; Chi, K N; van der Heijden, M S; Matsubara, N; Hussain, S; Flechon, A; Alekseev, B Y; Yu, E Y; Walgren, R A; Russo, F; Zimmermann, A H; Bell-Mcguinn, K M; Powles, T B
- Publisher
- Oxford University Press; Elsevier BV (ISSN 0923-7534)
- Published
- 2018
- Field
- Medicine (Health Sciences)